Exercise benefits for people with ATTR-CM may include: In general, says Ajay Vallakati, MBBS, an advanced heart failure and ...

Ken’s search for answers brought him to nearly a dozen doctors. After months of tests, he was finally diagnosed with a rare ...

This rare condition can’t be cured, but its symptoms can be treated. Take this assessment to learn what more you can do to manage the condition. Before you were diagnosed with transthyretin ...

Credit: Getty Images. The sNDA is supported by data from the phase 3, placebo-controlled APOLLO-B study. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug ...

Please provide your email address to receive an email when new articles are posted on . Alnylam announced positive top-line results of its phase 3 trial of vutrisiran for the treatment of ATTR ...

Swelling, or edema, is more than just a nuisance—it can feel like carrying extra baggage in your legs, ankles, or abdomen. ...

A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with ...

A report from the World Heart Federation provides an overview of transthyretin amyloid cardiomyopathy (ATTR-CM), including tools for diagnosis and patient management, highlighting the importance of ...

Novel directed therapies for transthyretin cardiac amyloidosis (ATTR) have been shown to improve outcomes and reduce the long-term negative effects of unchecked amyloid proliferation in patients with ...

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) announced Monday that the European Commission or EC has granted approval for AMVUTTRA (vutrisiran) for the treatment of wild-type or hereditary ...

Alnylam Pharmaceuticals Inc. ALNY said Wednesday its stock will be halted on Nasdaq through the day as a regulatory advisory committee will meet to review its new drug application for a treatment for ...

Intellia Therapeutics NTLA has made meaningful progress with the development of its in vivo programs. The company is currently advancing two late-stage in vivo candidates — lonvo-z (or, NTLA-2002) for ...